// App-Quantinova.ai

4194 : Assessment of novel benzosuberene-based vascular disrupting agents (VDA) on diverse tumor lines

Researchers

Presenter

  • Li Liu

Principal Investigators

  • Mary Lynn Trawick

  • Kevin Pinney

  • Ralph Peter Mason

Medical Centers

  • UTSouthwestern Medical Center, Dallas, TX

  • Baylor University, Waco, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

  • Breast cancer

  • Lung Cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • NSC-348103

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved